Phase III international randomized trial | APACT Investigators | n = 866 | Resected PDAC | Journal of Clinical Oncology 2019 **Tempero et al.** Margaret A. Tempero Published in Journal of Clinical Oncology, 2019 Enrollment: 2013–2016 [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/36521097/) --- ### Essential Takeaway APACT evaluated adjuvant gemcitabine plus nab-paclitaxel (Abraxane) versus gemcitabine alone after PDAC resection. Although the trial failed to meet its primary endpoint of independently assessed disease-free survival, secondary analyses and investigator-assessed outcomes favored the combination regimen, leaving interpretation controversial. The study demonstrated feasibility of intensified adjuvant therapy but did not clearly establish gemcitabine/nab-paclitaxel as a definitive postoperative standard. --- ### Clinical Question Does adjuvant gemcitabine plus nab-paclitaxel improve outcomes compared with gemcitabine alone after curative-intent resection of pancreatic ductal adenocarcinoma? --- ### Population - Resected PDAC - R0 or R1 resections - No metastatic disease - ECOG 0–1 Patients underwent surgery before enrollment without prior neoadjuvant therapy. --- ### Study Design #### Arm 1 — Gemcitabine Alone - Gemcitabine on days 1, 8, and 15 - 28-day cycles - 6 cycles total #### Arm 2 — Gemcitabine + Nab-Paclitaxel - Gemcitabine plus nab-paclitaxel - Days 1, 8, and 15 - 28-day cycles - 6 cycles total --- ### Endpoints #### Primary Endpoint Independently assessed disease-free survival (DFS) #### Secondary Endpoints - Investigator-assessed DFS - Overall survival (OS) - Safety/toxicity - Treatment completion rates --- ### Key Results #### Primary Endpoint The trial did not meet its primary endpoint: - Independently assessed DFS: - 19.4 vs 18.8 months - HR 0.88 - p = 0.18 No statistically significant DFS improvement was demonstrated. --- #### Investigator-Assessed DFS Investigator assessment favored combination therapy: - 16.6 vs 13.7 months - HR 0.82 - p = 0.02 This discrepancy became a major focus of interpretation and controversy. --- #### Overall Survival Median OS numerically favored gemcitabine/nab-paclitaxel: - 40.5 vs 36.2 months However, OS benefit did not clearly establish superiority. --- ### Toxicity Combination therapy increased: - neutropenia - fatigue - peripheral neuropathy Toxicity was expectedly greater than gemcitabine monotherapy but generally manageable. --- ### Additional Findings #### Demonstrated Feasibility of Intensified Adjuvant Therapy The trial showed that multi-agent postoperative chemotherapy could be delivered safely to selected patients after pancreatic resection. #### Highlighted Endpoint Assessment Challenges Differences between independent and investigator-assessed DFS highlighted challenges in radiographic interpretation and recurrence assessment in PDAC trials. --- ### Interpretation APACT became an important but controversial adjuvant PDAC trial because it technically failed its primary endpoint despite several signals favoring combination therapy. The study reinforced growing interest in intensified systemic therapy after resection but ultimately did not clearly change standard practice, particularly after the emergence of PRODIGE-24. The trial also highlighted the increasing difficulty of demonstrating incremental benefit beyond established adjuvant chemotherapy backbones. --- ### Important Limitations #### Primary Endpoint Negative - Independently assessed DFS did not significantly improve #### Endpoint Discordance - Investigator-assessed DFS differed substantially from centrally assessed DFS #### Toxicity Burden - Higher rates of neuropathy and hematologic toxicity #### Evolving Treatment Landscape - Results were rapidly overshadowed by PRODIGE-24 and mFOLFIRINOX #### Surgery-First Era - Conducted before widespread neoadjuvant adoption --- ### Practice Impact APACT did not establish gemcitabine/nab-paclitaxel as a dominant adjuvant standard but demonstrated that intensified postoperative systemic therapy was feasible and potentially beneficial. The trial contributed to the broader movement toward: - multi-agent adjuvant therapy - improved systemic disease control - escalation beyond gemcitabine monotherapy Although mFOLFIRINOX later became the preferred regimen for fit patients, APACT remains an important transitional trial in the evolution of modern adjuvant PDAC therapy.